Symptomatic therapy (such as acetylcholinesterase inhibitors) only regulates neurotransmitters; in terms of efficacy and safety, Donanemab showed that iADRS score delayed 35% cognitive decline in phase III trials (low/medium Tau subgroup was better) (Mintun et al., 2021), and Lecanemab (Clarity AD test) reduced CDR-SB by 27% (van Dyck et al., 2023), but both were accompanied by ARIA risk (edema 12.6%–17.3%). The gene discussed is ACHE; the disease is Alzheimer disease.